The study of immune checkpoint inhibitors in chronic hepatitis B virus infection

被引：7

作者：

Li, Siyu ^{[1
]}

Li, Na ^{[1
]}

Yang, Shanru ^{[1
,2
]}

Deng, Haiyan ^{[1
]}

Li, Yanguo ^{[3
]}

Wang, Yixuan ^{[1
]}

Yang, Jiaqiang ^{[1
]}

Lv, Jiaxin ^{[1
]}

Dong, Lan ^{[1
]}

Yu, Guansen ^{[1
]}

Hou, Xin ^{[1
]}

Wang, Geng ^{[1
]}

机构：

[1] Ningbo Univ, Sch Med, Ningbo 315211, Peoples R China

[2] Harbin Med Univ, Dept Histol & Embryol, Harbin 150081, Peoples R China

[3] Ningbo Univ, Inst Drug Discovery Technol, Ningbo, Peoples R China

来源：

INTERNATIONAL IMMUNOPHARMACOLOGY | 2022年 / 109卷

基金：

中国国家自然科学基金; 中国博士后科学基金;

关键词：

Hepatitis B virus; Chronic hepatitis B; Immune checkpoint inhibitors; CD8; T-CELLS; UP-REGULATION; THERAPEUTIC VACCINATION; AUTOIMMUNE-DISEASES; VIRAL-HEPATITIS; TIM-3; EXPRESSION; PD-1; ACTIVATION; BLOCKADE;

D O I：

10.1016/j.intimp.2022.108842

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Chronic hepatitis B (CHB) is a contagious disease caused by the hepatitis B virus, which can damage the liver via cirrhosis or cancer. Existing CHB treatments are not completely effective; immune checkpoint inhibitors show potential hope for treating CHB, but their safety and efficacy need to be further validated. In this review, we introduce the mechanisms of CHB virus infection, the expression of immune checkpoints during CHB, and the treatments that are currently available. Finally, we discuss the possibilities for using immune checkpoint inhibitors to treat CHB.

引用

页数：9

共 50 条

[1] Effect of immune checkpoint inhibitors on patients with hepatitis B virus infection
Mon, Hsien-Chen
Lee, Pei-Chang
Chi, Chen-Ta
Huang, Yi-Hsiang
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2025, 88 (02) : 93 - 97
[2] Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection
Hagiwara, Satoru
Nishida, Naoshi
Ida, Hiroshi
Ueshima, Kazuomi
Minami, Yasunori
Takita, Masahiro
Aoki, Tomoko
Morita, Masahiro
Chishina, Hirokazu
Komeda, Yoriaki
Yoshida, Akihiro
Hayashi, Hidetoshi
Nakagawa, Kazuhiko
Kudo, Masatoshi
HEPATOLOGY RESEARCH, 2022, 52 (09) : 754 - 761
[3] Are immune-checkpoint inhibitors immunosuppressive to hepatitis B virus?
George Lau
Ming-Lung Yu
Grace Wong
Alexander Thompson
Hepatology International, 2022, 16 : 482 - 483
[4] Are immune-checkpoint inhibitors immunosuppressive to hepatitis B virus?
Lau, George
Yu, Ming-Lung
Wong, Grace
Thompson, Alexander
HEPATOLOGY INTERNATIONAL, 2022, 16 (02) : 482 - 483
[5] Immune therapy of hepatitis B virus chronic infection
Pol, S
Michel, ML
Bréchot, C
HEPATOLOGY, 2000, 31 (02) : 548 - 549
[6] Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection
Alkrekshi, Akram
Tamaskar, Ila
ONCOLOGIST, 2021, 26 (05): : E827 - E830
[7] Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors
Burns, Ethan A.
Muhsen, Ibrahim N.
Anand, Kartik
Xu, Jiaqiong
Umoru, Godsfavour
Arain, Abeer N.
Abdelrahim, Maen
JOURNAL OF IMMUNOTHERAPY, 2021, 44 (03) : 132 - 139
[8] SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN CANCER PATIENTS WITH CHRONIC HEPATITIS C INFECTION: A PROSPECTIVE OBSERVATIONAL STUDY
Yibirin, Marcel
Pundhir, Pooja
Yepez-Guevara, Eduardo
Granwehr, Bruno
Kaseb, Ahmed
Patel, Sapna
Naing, Aung
Shah, Amishi Y.
Skoulidis, Ferdinandos
Tawbi, Hussein A.
Zhang, Hao Chi
Wang, Lan
Miller, Ethan D.
Torres, Harrys A.
HEPATOLOGY, 2020, 72 : 571A - 572A
[9] Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors
Mustafayev, Khalis
Mallet, Vincent
Torres, Harrys A.
JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2024, 7 (02) : 111 - 121
[10] Hepatitis B virus reactivation risk associated with immune checkpoint inhibitors in tumor treatment: a retrospective study
Yin, Yue
Liu, Bao Jiang
Zhang, Yan Hua
Qiu, Xin Ye
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (12) : 1288 - 1297

← 1 2 3 4 5 →